Ensysce Biosciences (ENSC) Non Operating Income (2020 - 2025)
Ensysce Biosciences (ENSC) posted quarterly Non Operating Income of $11967.0 for Q3 2025, down 29.7% year-over-year from $17023.0 in Q3 2024, and down 29.6% quarter-over-quarter from $16998.0 in Q2 2025.
Ensysce Biosciences (ENSC) Non Operating Income (2020 - 2025) Analysis & Trends
Ensysce Biosciences (ENSC) has reported Non Operating Income for 6 consecutive years, with $11967.0 the latest figure, recorded in Q3 2025.
- In Q3 2025, Non Operating Income fell 29.7% year-over-year to $11967.0; the TTM figure through Sep 2025 stood at $62958.0 (up 103.89% YoY), while the FY2024 annual figure was -$1.3 million, down 1467.48% from the prior year.
- Non Operating Income fell to $11967.0 in Q3 2025 per ENSC's latest filing, from $16998.0 in the prior quarter.
- Across five years, Non Operating Income topped out at $3.9 million in Q1 2022 and bottomed at -$8.0 million in Q4 2021.
- Historically, Non Operating Income has averaged -$546058.7 across 5 years, with a median of $11967.0 in 2025.
- On a YoY basis, Non Operating Income climbed as much as 1094.24% in 2022 and fell as far as 1080.84% in 2022.
- Ensysce Biosciences' Non Operating Income stood at -$8.0 million in 2021, then jumped by 109.0% to $722710.0 in 2022, then tumbled by 148.25% to -$348676.0 in 2023, then jumped by 103.46% to $12054.0 in 2024, then retreated by 0.72% to $11967.0 in 2025.
- Business Quant data shows ENSC's Non Operating Income at $11967.0 in Q3 2025, $16998.0 in Q2 2025, and $21939.0 in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 234.30 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -53.64 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -51.63 Mn |
| 10 | Ensysce Biosciences | 942,649.19 | -3.37 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 11,967.00 |
| Jun 30, 2025 | 16,998.00 |
| Mar 31, 2025 | 21,939.00 |
| Dec 31, 2024 | 12,054.00 |
| Sep 30, 2024 | 17,023.00 |
| Jun 30, 2024 | -12,351.00 |
| Mar 31, 2024 | -1.27 Mn |
| Dec 31, 2023 | -348,676.00 |
| Sep 30, 2023 | 16,508.00 |
| Jun 30, 2023 | 54,652.00 |
| Mar 31, 2023 | 369,429.00 |
| Dec 31, 2022 | 722,710.00 |
| Sep 30, 2022 | -3.69 Mn |
| Jun 30, 2022 | -867,937.00 |
| Mar 31, 2022 | 3.85 Mn |
| Dec 31, 2021 | -8.03 Mn |
| Sep 30, 2021 | -312,679.00 |
| Jun 30, 2021 | -544,994.00 |
| Mar 31, 2021 | -387,419.00 |
| Dec 31, 2020 | 1.11 Mn |